__NUXT_JSONP__("/drugs/Tafasitamab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:a,conditionIndication:"Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).",inn:"tafasitamab",marketingAuthorisationDate:"2021-08-26 00:00:00",marketingAuthorisationHolder:"Incyte Biosciences Distribution B.V.",medicineName:"Minjuvi",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fminjuvi"}],fdaDrugLabel:[{brand:"MONJUVI",indication:"1 INDICATIONS AND USAGE MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). MONJUVI is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )",manufacturer:"MorphoSys US Inc.",splSetId:"ec13ac6b-bfde-4e84-907a-83bd69584d95"}],id:a,nciThesaurus:{casRegistry:"1422527-84-1",chebiId:b,chemicalFormula:b,definition:"An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.",fdaUniiCode:"QQA9MLH692",identifier:"C95768",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C112889"],synonyms:["Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer","MOR-00208","MOR00208","MOR208","Monjuvi","TAFASITAMAB",a,"Tafasitamab-cxix","XmAb5574"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FTafasitamab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Tafasitamab","","2021-10-30T13:48:10.463Z")));